

# Cardiovascular Magnetic Resonance Imaging

Textbook and Atlas

Bearbeitet von  
Vinzenz Hombach, Nico Merkle, Volker Rasche

1., Auflage 2012 2012. Buch. 512 S. Hardcover  
ISBN 978 3 7945 2799 1  
Format (B x L): 21 x 28 cm  
Gewicht: 1928 g

[Weitere Fachgebiete > Medizin > Klinische und Innere Medizin > Kardiologie, Angiologie, Phlebologie](#)

Zu [Leseprobe](#)

schnell und portofrei erhältlich bei

The logo for beck-shop.de features the text 'beck-shop.de' in a bold, red, sans-serif font. Above the 'i' in 'shop' are three red dots of increasing size. Below the main text, 'DIE FACHBUCHHANDLUNG' is written in a smaller, red, all-caps, sans-serif font.

**beck-shop.de**  
DIE FACHBUCHHANDLUNG

Die Online-Fachbuchhandlung [beck-shop.de](http://beck-shop.de) ist spezialisiert auf Fachbücher, insbesondere Recht, Steuern und Wirtschaft. Im Sortiment finden Sie alle Medien (Bücher, Zeitschriften, CDs, eBooks, etc.) aller Verlage. Ergänzt wird das Programm durch Services wie Neuerscheinungsdienst oder Zusammenstellungen von Büchern zu Sonderpreisen. Der Shop führt mehr als 8 Millionen Produkte.

# Contents

## Part I

### Basic Technology

|            |                                                               |           |
|------------|---------------------------------------------------------------|-----------|
| <b>1</b>   | <b>Basic Principles of Cardiac Magnetic Resonance Imaging</b> | <b>3</b>  |
|            | Volker Rasche and Tobias Schäffter                            |           |
| <b>1.1</b> | <b>Nuclear Spin and Magnetic Moment</b>                       | <b>3</b>  |
| 1.1.1      | Excitation of the Spin System                                 | 4         |
| 1.1.2      | Chemical Shift                                                | 5         |
| 1.1.3      | Relaxation Processes                                          | 5         |
| 1.1.4      | Spin Echo Experiment                                          | 6         |
| <b>1.2</b> | <b>Contrast</b>                                               | <b>6</b>  |
| 1.2.1      | Intrinsic Contrast                                            | 7         |
| 1.2.2      | Exogenous Contrast                                            | 8         |
| <b>1.3</b> | <b>MR Imaging</b>                                             | <b>9</b>  |
| <b>1.4</b> | <b>Slice Selection</b>                                        | <b>9</b>  |
| <b>1.5</b> | <b>Spatial Encoding of the MR Signal</b>                      | <b>9</b>  |
| 1.5.1      | k-Space Encoding                                              | 10        |
| <b>1.6</b> | <b>Basic MRI Pulse Sequences</b>                              | <b>12</b> |
| 1.6.1      | Spin Echo-Based Techniques (SE)                               | 12        |
| 1.6.2      | Gradient Echo-Based Techniques (GE)                           | 12        |
| <b>1.7</b> | <b>Motion Synchronization in CMR Imaging</b>                  | <b>13</b> |
| 1.7.1      | ECG-Triggered Data Acquisition                                | 13        |
| 1.7.2      | Respiratory-Gated Data Acquisition                            | 14        |
| <b>1.8</b> | <b>Spin Preparation</b>                                       | <b>15</b> |
| 1.8.1      | Preparation per Heart Beat                                    | 15        |
| 1.8.2      | Preparation per Heart Phase                                   | 17        |
| 1.8.3      | Preparation per Excitation                                    | 18        |
| <b>1.9</b> | <b>Rapid MR Imaging Techniques</b>                            | <b>19</b> |
| 1.9.1      | Partial k-Space Coverage                                      | 20        |
| 1.9.2      | Acquisition of Larger k-Space Segments per Excitation         | 20        |
| 1.9.3      | Parallel Imaging and k-t Acceleration Techniques              | 21        |

|             |                                       |           |
|-------------|---------------------------------------|-----------|
| <b>1.10</b> | <b>MR Angiography (MRA)</b>           | <b>22</b> |
| 1.10.1      | Inflow Techniques                     | 22        |
| 1.10.2      | Contrast-Enhanced Techniques (CE-MRA) | 23        |
| 1.10.3      | Phase Contrast Techniques (PCA)       | 23        |
| <b>1.11</b> | <b>Signal-to-Noise Considerations</b> | <b>24</b> |
| 1.11.1      | MRI Sequence                          | 24        |
| 1.11.2      | Main Magnetic Field Strength          | 24        |
| 1.11.3      | Pixel Voxel Size                      | 24        |
| 1.11.4      | Acquisition Time                      | 24        |
| 1.11.5      | Receive Coils                         | 25        |
| 1.11.6      | SNR Optimization                      | 26        |
|             | <b>References</b>                     | <b>26</b> |

|            |                                                             |           |
|------------|-------------------------------------------------------------|-----------|
| <b>2</b>   | <b>Cardiac Magnetic Resonance Imaging Laboratory</b>        | <b>28</b> |
|            | Nico Merkle and Axel Bornstedt                              |           |
| <b>2.1</b> | <b>Introduction</b>                                         | <b>28</b> |
| <b>2.2</b> | <b>Site Planning</b>                                        | <b>28</b> |
| <b>2.3</b> | <b>CMR-Facility Room Configuration</b>                      | <b>29</b> |
| <b>2.4</b> | <b>Hardware</b>                                             | <b>30</b> |
| 2.4.1      | Magnet                                                      | 30        |
| 2.4.2      | Gradients                                                   | 31        |
| 2.4.3      | Radiofrequency (RF) System                                  | 31        |
| 2.4.4      | Computer Control Systems, Operator Console and Workstations | 32        |
| <b>2.5</b> | <b>Software</b>                                             | <b>32</b> |
| <b>2.6</b> | <b>Safety Aspects</b>                                       | <b>33</b> |
| 2.6.1      | Static Magnetic Field                                       | 33        |
| 2.6.2      | Alternating Magnetic Field Gradients                        | 34        |
| 2.6.3      | Radiofrequency Energy                                       | 34        |
| <b>2.7</b> | <b>MRI Safety and Compatibility</b>                         | <b>34</b> |
| <b>2.8</b> | <b>Emergency Management</b>                                 | <b>35</b> |
| <b>2.9</b> | <b>Contraindications to MRI</b>                             | <b>35</b> |
|            | <b>References</b>                                           | <b>35</b> |

|            |                                                                               |    |
|------------|-------------------------------------------------------------------------------|----|
| <b>3</b>   | <b>Contrast Agents for Magnetic Resonance Imaging – Recent Advances</b> ..... | 37 |
|            | Dipanjan Pan and Gregory M. Lanza                                             |    |
| <b>3.1</b> | <b>Introduction</b> .....                                                     | 37 |
| <b>3.2</b> | <b>Contrast Materials for MRI – General Consideration</b> .....               | 37 |
| 3.2.1      | Contrast Materials and Broader Classifications .....                          | 37 |
| 3.2.2      | T1 Small Molecule Contrast Agents .....                                       | 39 |
| 3.2.3      | Nanoparticle-Based Agents .....                                               | 42 |
| <b>3.3</b> | <b>Conclusions</b> .....                                                      | 47 |
|            | <b>References</b> .....                                                       | 47 |

## Part II

### Clinical Applications

---

|            |                                                                    |    |
|------------|--------------------------------------------------------------------|----|
| <b>4</b>   | <b>Cardiac Magnetic Resonance Examination of the Patient</b> ..... | 55 |
|            | Nico Merkle and Vinzenz Hombach                                    |    |
| <b>4.1</b> | <b>Introduction</b> .....                                          | 55 |
| <b>4.2</b> | <b>Patient Informed Consent</b> .....                              | 55 |
| <b>4.3</b> | <b>General Patient Preparation</b> .....                           | 56 |
| 4.3.1      | Positioning and ECG Electrode Placement ...                        | 56 |
| 4.3.2      | Breath-Hold Instructions .....                                     | 57 |
| 4.3.3      | Coil Placement and Positioning in the Scanner .....                | 57 |
| <b>4.4</b> | <b>Specific Patient Preparation</b> .....                          | 57 |
| 4.4.1      | Stress Testing .....                                               | 57 |
| 4.4.2      | Pediatric and Neonatal CMR .....                                   | 58 |
| <b>4.5</b> | <b>Practice of CMR Measurements</b> .....                          | 58 |
| 4.5.1      | Imaging of Cardiac Position .....                                  | 58 |
| 4.5.2      | Functional Analysis of the Heart .....                             | 62 |
| 4.5.3      | Specially Adapted Imaging Planes .....                             | 63 |
| 4.5.4      | Flow Measurement (PC Flow Mapping) .....                           | 63 |
| 4.5.5      | Imaging of Cardiac Valves .....                                    | 63 |
| 4.5.6      | Imaging of Cardiac Anatomy .....                                   | 64 |
| <b>4.6</b> | <b>Computing and Report</b> .....                                  | 64 |

|            |                                                                                                                  |    |
|------------|------------------------------------------------------------------------------------------------------------------|----|
| <b>5</b>   | <b>Topographic Anatomy, Structure and Function of the Heart</b> .....                                            | 65 |
|            | Vinzenz Hombach                                                                                                  |    |
| <b>5.1</b> | <b>Topographic Anatomy of the Heart and Great Vessels</b> .....                                                  | 65 |
| <b>5.2</b> | <b>Structural Characteristics of Atria, Ventricles, Coronary Arteries and the Pericardium on CMR Imaging</b> ... | 66 |
| 5.2.1      | Atria .....                                                                                                      | 66 |
| 5.2.2      | Ventricles .....                                                                                                 | 68 |
| 5.2.3      | Cardiac Valves .....                                                                                             | 70 |
| 5.2.4      | Coronary Arteries .....                                                                                          | 70 |
| 5.2.5      | Pericardium .....                                                                                                | 70 |
| <b>5.3</b> | <b>CMR Projection Planes</b> .....                                                                               | 71 |
| 5.3.1      | Body Axes Oriented Imaging Planes .....                                                                          | 71 |
| 5.3.2      | Cardiac Oriented Imaging Planes .....                                                                            | 71 |
| <b>5.4</b> | <b>Ventricular Performance</b> .....                                                                             | 71 |
| <b>5.5</b> | <b>Quantitative Assessment of RV and LV Function and Muscle Mass</b> .....                                       | 75 |
| 5.5.1      | Geometrical Models .....                                                                                         | 75 |
| 5.5.2      | Volumetry Using Simpson's Rule .....                                                                             | 77 |
| <b>5.6</b> | <b>Assessment of Regional Ventricular Function</b> .....                                                         | 80 |
| 5.6.1      | Regional Wall Thickness .....                                                                                    | 80 |
| 5.6.2      | Myocardial Tagging .....                                                                                         | 81 |
| 5.6.3      | Velocity-Encoded Tissue Imaging (Wall Velocity Mapping) .....                                                    | 84 |
| <b>5.7</b> | <b>Assessment of Diastolic Function</b> .....                                                                    | 84 |
| 5.7.1      | Time-Volume Relationship .....                                                                                   | 84 |
| 5.7.2      | Mitral Valve Inflow and Pulmonary Vein Phase Velocity Mapping .....                                              | 84 |
| 5.7.3      | Myocardial Tissue Velocity Mapping .....                                                                         | 85 |
| 5.7.4      | Myocardial Tissue Tagging .....                                                                                  | 87 |
| <b>5.8</b> | <b>Measurement of Flow in the Aorta and Pulmonary Artery</b> .....                                               | 87 |
| <b>5.9</b> | <b>Assessment of Biophysical Mechanical Properties of the Aortic Wall</b> .....                                  | 87 |
|            | <b>References</b> .....                                                                                          | 88 |

|                         |                                                                                                    |     |                         |                                                                                      |     |
|-------------------------|----------------------------------------------------------------------------------------------------|-----|-------------------------|--------------------------------------------------------------------------------------|-----|
| <b>6</b>                | <b>Coronary Artery Disease –<br/>Stable Angina</b> .....                                           | 91  | <b>7.4</b>              | <b>CMR Sequences and Protocols</b> .....                                             | 118 |
|                         | Nico Merkle                                                                                        |     | <b>7.5</b>              | <b>CMR Examinations in Patients with UA</b> ..                                       | 119 |
| <b>6.1</b>              | <b>Definition</b> .....                                                                            | 91  | 7.5.1                   | CMR-Based Diagnosis of Structure<br>and Function/Dysfunction of the Heart .....      | 119 |
| <b>6.2</b>              | <b>Physiology of Coronary Circulation</b> .....                                                    | 92  | 7.5.2                   | Assessment of Myocardial Viability –<br>Pathophysiology of LGE .....                 | 119 |
| 6.2.1                   | Myocardial Oxygen Supply and Consumption<br>and Coronary Blood Flow (CBF) .....                    | 92  | <b>7.6</b>              | <b>CMR Examinations in Patients<br/>with NSTEMI and STEMI</b> .....                  | 119 |
| 6.2.2                   | Endothelial Dysfunction .....                                                                      | 94  | 7.6.1                   | Assessment of Infarct Size and Myocardial<br>Area at Risk in the Acute Setting ..... | 119 |
| <b>6.3</b>              | <b>Pathophysiology<br/>of Myocardial Ischemia</b> .....                                            | 94  | 7.6.2                   | Detection of Infarct Complications .....                                             | 122 |
| 6.3.1                   | Effects of Coronary Stenoses<br>on Coronary Blood Flow .....                                       | 94  | 7.6.3                   | Prediction of Left Ventricular Remodeling ...                                        | 124 |
| 6.3.2                   | Role of Coronary Collateral Circulation ....                                                       | 96  | 7.6.4                   | Assessment of Post-Myocardial Infarction<br>Prognosis .....                          | 125 |
| 6.3.3                   | Metabolic and Functional Consequences<br>of Myocardial Ischemia .....                              | 96  | 7.6.5                   | Assessment of Therapeutic Interventions ....                                         | 128 |
| <b>6.4</b>              | <b>Etiology and Pathogenesis<br/>of Coronary Atherosclerosis</b> .....                             | 97  | <b>7.7</b>              | <b>Non-Invasive Triage of Patients<br/>with Acute Chest Pain</b> .....               | 129 |
| <b>6.5</b>              | <b>Clinical Presentation and Therapy</b> .....                                                     | 97  | <b>7.8</b>              | <b>Summary and Conclusions</b> .....                                                 | 129 |
| <b>6.6</b>              | <b>CMR Protocols</b> .....                                                                         | 97  | <b>7.9</b>              | <b>Future Perspectives</b> .....                                                     | 130 |
| 6.6.1                   | CMR-Based Diagnosis of Structure<br>and Function/Dysfunction of the Heart .....                    | 97  | <b>References</b> ..... |                                                                                      | 131 |
| 6.6.2                   | Detection of Myocardial Ischemia<br>and Diagnostic Performance of the Tests ....                   | 98  | <b>8</b>                | <b>Magnetic Resonance<br/>Coronary Angiography<br/>and Vessel Wall Imaging</b> ..... | 134 |
| 6.6.3                   | First-Pass Perfusion .....                                                                         | 101 |                         | Won Yong Kim, René Botnar and Volker Rasche                                          |     |
| 6.6.4                   | Assessment of Myocardial Viability .....                                                           | 107 | <b>8.1</b>              | <b>Introduction</b> .....                                                            | 134 |
| <b>6.7</b>              | <b>Conclusions</b> .....                                                                           | 110 | <b>8.2</b>              | <b>Motion Compensation</b> .....                                                     | 134 |
| <b>6.8</b>              | <b>Future Perspectives</b> .....                                                                   | 110 | 8.2.1                   | Cardiac Motion .....                                                                 | 134 |
| <b>References</b> ..... |                                                                                                    | 111 | 8.2.2                   | Respiratory Motion .....                                                             | 135 |
| <b>7</b>                | <b>Coronary Artery Disease –<br/>Acute Coronary Syndromes</b> .....                                | 115 | <b>8.3</b>              | <b>Imaging Techniques</b> .....                                                      | 135 |
|                         | Loren Budge, Christopher M. Kramer<br>and Peter Bernhardt                                          |     | 8.3.1                   | Coronary Artery Imaging .....                                                        | 135 |
| <b>7.1</b>              | <b>Definition and Spectrum</b> .....                                                               | 115 | 8.3.2                   | Coronary Vein Imaging .....                                                          | 137 |
| <b>7.2</b>              | <b>Etiology and Pathophysiology</b> .....                                                          | 116 | 8.3.3                   | Coronary Arterial Wall Imaging .....                                                 | 137 |
| <b>7.3</b>              | <b>Clinical Presentation and Therapy</b> .....                                                     | 117 | <b>8.4</b>              | <b>Planning of a Coronary MRI<br/>Examination</b> .....                              | 138 |
| 7.3.1                   | Relevance of Clinical Signs<br>of Acute Coronary Syndromes (ACS) .....                             | 117 | <b>8.5</b>              | <b>Clinical Application</b> .....                                                    | 140 |
| 7.3.2                   | ST-Elevation Myocardial Infarction<br>(STEMI or STE-ACS) .....                                     | 117 | 8.5.1                   | Coronary Angiography .....                                                           | 140 |
| 7.3.3                   | Non-ST-Elevation Myocardial Infarction<br>(NSTEMI or NSTEMI-ACS)<br>and Unstable Angina (UA) ..... | 117 | 8.5.2                   | Coronary Anomalies and Aneurysm .....                                                | 142 |
|                         |                                                                                                    |     | 8.5.3                   | Coronary Bypass Grafts .....                                                         | 144 |
|                         |                                                                                                    |     | 8.5.4                   | Coronary Vessel Wall .....                                                           | 144 |
|                         |                                                                                                    |     | 8.5.5                   | Coronary Vein Imaging .....                                                          | 145 |
|                         |                                                                                                    |     | <b>8.6</b>              | <b>Future Perspectives</b> .....                                                     | 145 |
|                         |                                                                                                    |     | <b>References</b> ..... |                                                                                      | 146 |

|                         |                                                                                |     |                         |                                                                                                        |     |
|-------------------------|--------------------------------------------------------------------------------|-----|-------------------------|--------------------------------------------------------------------------------------------------------|-----|
| <b>9</b>                | <b>Assessment of Myocardial Blood Flow and Oxygenation</b> .....               | 149 | <b>10.12</b>            | <b>Cardiac Involvement in Neuromuscular Diseases (NMD)</b> .....                                       | 179 |
|                         | Vinzenz Hombach and Volker Rasche                                              |     | <b>10.13</b>            | <b>Drug Induced Cardiomyopathy</b> .....                                                               | 181 |
| <b>9.1</b>              | <b>Physiology of Coronary Circulation and Myocardial Oxygen Consumption</b> .. | 149 | <b>10.14</b>            | <b>Post-Partum Cardiomyopathy/ Peri-Partum Cardiomyopathy (PPCM)</b> ...                               | 182 |
| <b>9.2</b>              | <b>CMR Protocol for Myocardial Blood Flow and BOLD Imaging</b> .....           | 150 | <b>10.15</b>            | <b>Conclusions and Future Perspectives</b> ...                                                         | 183 |
| <b>9.3</b>              | <b>Coronary and Myocardial Blood Flow and Flow Reserve</b> .....               | 150 | <b>References</b> ..... | 184                                                                                                    |     |
| 9.3.1                   | Native Coronary Arteries .....                                                 | 150 | <b>11</b>               | <b>Acute Myocarditis and Chronic Inflammatory Cardiomyopathy</b> .....                                 | 187 |
| 9.3.2                   | Coronary Artery Bypass Grafts (CABG) ....                                      | 151 |                         | Ralf Wassmuth and Jeanette Schulz-Menger                                                               |     |
| 9.3.3                   | Coronary Sinus (CS) .....                                                      | 152 | <b>11.1</b>             | <b>Definition</b> .....                                                                                | 187 |
| <b>9.4</b>              | <b>Myocardial Oxygenation by BOLD Imaging</b> .....                            | 154 | <b>11.2</b>             | <b>Etiology and Pathogenesis</b> .....                                                                 | 187 |
| 9.4.1                   | Theoretical Background .....                                                   | 154 | <b>11.3</b>             | <b>Clinical Presentation, Natural History and Therapy</b> .....                                        | 188 |
| 9.4.2                   | Animal Studies .....                                                           | 154 | <b>11.4</b>             | <b>CMR Protocols</b> .....                                                                             | 188 |
| 9.4.3                   | Human Studies .....                                                            | 154 | 11.4.1                  | Cine Imaging .....                                                                                     | 188 |
| <b>9.5</b>              | <b>Conclusions and Future Perspectives</b> ...                                 | 156 | 11.4.2                  | T2-Weighted Imaging .....                                                                              | 188 |
| <b>References</b> ..... | 156                                                                            |     | 11.4.3                  | Early Contrast Enhancement .....                                                                       | 189 |
| <b>10</b>               | <b>Cardiomyopathies</b> .....                                                  | 158 | 11.4.4                  | Late Gadolinium Enhancement .....                                                                      | 189 |
|                         | Vinzenz Hombach and Markus Kunze                                               |     | <b>11.5</b>             | <b>CMR-Based Assessment of Cardiac Structure and Function and Myocardial Tissue Characteristics</b> .. | 189 |
| <b>10.1</b>             | <b>Definition</b> .....                                                        | 158 | 11.5.1                  | Cine Imaging .....                                                                                     | 189 |
| <b>10.2</b>             | <b>CMR Protocols</b> .....                                                     | 158 | 11.5.2                  | Edema .....                                                                                            | 189 |
| <b>10.3</b>             | <b>Idiopathic Dilated Cardiomyopathy (IDCM)</b> .....                          | 159 | 11.5.3                  | Hyperemia and Capillary Leakage .....                                                                  | 190 |
| <b>10.4</b>             | <b>Hypertrophic Cardiomyopathy (HCM)</b> ..                                    | 161 | 11.5.4                  | Fibrotic Lesions .....                                                                                 | 190 |
| <b>10.5</b>             | <b>Restrictive Cardiomyopathy</b> .....                                        | 165 | <b>11.6</b>             | <b>Characterization</b> .....                                                                          | 191 |
| <b>10.6</b>             | <b>Arrhythmogenic Right Ventricular Cardiomyopathy or Dysplasia (ARVD)</b> ..  | 166 | <b>11.7</b>             | <b>Special Inflammatory Myocardial Diseases</b> .....                                                  | 191 |
| <b>10.7</b>             | <b>Tako-Tsubo Cardiomyopathy</b> .....                                         | 168 | 11.7.1                  | Chagas Disease .....                                                                                   | 192 |
| <b>10.8</b>             | <b>Cardiac Non-Compaction (NC)</b> .....                                       | 169 | 11.7.2                  | Systemic Lupus Erythematosus (SLE) .....                                                               | 192 |
| <b>10.9</b>             | <b>Secondary Types of Restrictive Cardiomyopathy</b> .....                     | 170 | 11.7.3                  | Churg-Strauss Syndrome (CSS) .....                                                                     | 192 |
| 10.9.1                  | Amyloidosis .....                                                              | 170 | 11.7.4                  | Wegener's Granulomatosis .....                                                                         | 192 |
| 10.9.2                  | Sarcoidosis .....                                                              | 172 | 11.7.5                  | Scleroderma .....                                                                                      | 193 |
| 10.9.3                  | Hemochromatosis .....                                                          | 174 | 11.7.6                  | Sarcoidosis .....                                                                                      | 193 |
| 10.9.4                  | Further Storage Diseases .....                                                 | 175 | 11.7.7                  | Rheumatoid Arthritis .....                                                                             | 194 |
| <b>10.10</b>            | <b>Endomyocardial Diseases</b> .....                                           | 176 | <b>11.8</b>             | <b>Summary and Conclusions</b> .....                                                                   | 194 |
| <b>10.11</b>            | <b>Carcinoid Syndrome of the Heart</b> .....                                   | 178 | <b>11.9</b>             | <b>Future Perspectives</b> .....                                                                       | 194 |
|                         |                                                                                |     | <b>References</b> ..... | 195                                                                                                    |     |

|                             |                                                                                 |     |                             |                                                                                    |     |
|-----------------------------|---------------------------------------------------------------------------------|-----|-----------------------------|------------------------------------------------------------------------------------|-----|
| <b>12</b>                   | <b>Heart Failure and Cardiac Transplantation</b> . . . . .                      | 198 | <b>13.3</b>                 | <b>Identification of Valve Stenosis and Regurgitation by Signal Void</b> . . . . . | 217 |
|                             | Raymond Kim, Igor Klem and Vinzenz Hombach                                      |     | <b>13.4</b>                 | <b>Quantification of Valve Opening and Stenosis</b> . . . . .                      | 217 |
| <b>12.1</b>                 | <b>Definition and Epidemiology</b> . . . . .                                    | 198 | 13.4.1                      | Direct Planimetry of Anatomical Valve Area . .                                     | 217 |
| <b>12.2</b>                 | <b>Etiology and Pathogenesis</b> . . . . .                                      | 198 | 13.4.2                      | Indirect Assessment of Effective Valve Opening Using Continuity Equation . . . . . | 219 |
| <b>12.3</b>                 | <b>Clinical Presentation and Diagnosis</b> . . . .                              | 199 | 13.4.3                      | Pressure Gradients . . . . .                                                       | 220 |
| <b>12.4</b>                 | <b>Prognosis and Therapy</b> . . . . .                                          | 200 | <b>13.5</b>                 | <b>Quantitative Measurements of Severity of Valve Regurgitation</b> . . . . .      | 220 |
| <b>12.5</b>                 | <b>CMR Protocols</b> . . . . .                                                  | 201 | 13.5.1                      | Evaluation of Anatomical Regurgitant Orifice . . . . .                             | 220 |
| <b>12.6</b>                 | <b>CMR-Based Diagnosis of Structure and Dysfunction of the Heart</b> . . . . .  | 201 | 13.5.2                      | Quantification of Regurgitant Volume . . . . .                                     | 221 |
| <b>12.7</b>                 | <b>Identification of Etiology and Systematic Diagnostic Approach</b> . . .      | 202 | <b>13.6</b>                 | <b>Evaluation of Valve Morphology and Mechanism of Dysfunction</b> . . . . .       | 222 |
| 12.7.1                      | Detection of Myocardial Damage/Scar by DE-CMR . . . . .                         | 202 | <b>13.7</b>                 | <b>Evaluation of Physiological Consequences of Valve Disease</b> . . . . .         | 222 |
| 12.7.2                      | Stepwise Diagnostic Approach . . . . .                                          | 204 | <b>13.8</b>                 | <b>Place of CMR in the Evaluation of Specific Valvular Diseases</b> . . . . .      | 222 |
| <b>12.8</b>                 | <b>Outcome Studies in Heart Failure</b> . . . . .                               | 206 | 13.8.1                      | Aortic Valve Disease . . . . .                                                     | 222 |
| <b>12.9</b>                 | <b>Assessment of LV Dyssynchrony</b> . . . . .                                  | 206 | 13.8.2                      | Mitral Valve Disease . . . . .                                                     | 226 |
| 12.9.1                      | Velocity-Encoded CMR and 3D LV Contraction Analysis . . . . .                   | 206 | 13.8.3                      | Tricuspid Valve Disease . . . . .                                                  | 230 |
| 12.9.2                      | Role of Myocardial Scarring . . . . .                                           | 207 | 13.8.4                      | Pulmonary Valve Disease . . . . .                                                  | 231 |
| 12.9.3                      | Prognostic Impact of CMR Derived Dyssynchrony . . . . .                         | 207 | 13.8.5                      | Evaluation of Valvular Masses and Tumors . .                                       | 232 |
| 12.9.4                      | MR Angiography of Coronary Veins . . . . .                                      | 208 | 13.8.6                      | Evaluation of Prosthetic Valves . . . . .                                          | 232 |
| <b>12.10</b>                | <b>Prognostic Information</b> . . . . .                                         | 208 | <b>13.9</b>                 | <b>Summary and Conclusions</b> . . . . .                                           | 232 |
| <b>12.11</b>                | <b>Cardiac Transplantation</b> . . . . .                                        | 209 | <b>References</b> . . . . . | 233                                                                                |     |
| 12.11.1                     | Surgical Technique . . . . .                                                    | 209 | <b>14</b>                   | <b>Congenital Heart Disease (CHD)</b> . . . .                                      | 236 |
| 12.11.2                     | Pathophysiology, Clinical Course, Complications and Prognosis . . . . .         | 209 |                             | Philipp Beerbaum, Christoph Galm and Jochen Spiess                                 |     |
| 12.11.3                     | Detection of Hemodynamic Alterations and Peri-Operative Complications . . . . . | 209 | <b>14.1</b>                 | <b>Introduction</b> . . . . .                                                      | 237 |
| 12.11.4                     | Allograft Rejection in Animals and Humans . .                                   | 210 | <b>14.2</b>                 | <b>General Clinical Signs and Symptoms</b> . .                                     | 237 |
| 12.11.5                     | Long-Term Allograft Surveillance . . . . .                                      | 211 | <b>14.3</b>                 | <b>Systematic Analysis of CHD</b> . . . . .                                        | 238 |
| <b>12.12</b>                | <b>Conclusions and Future Perspectives</b> . . .                                | 212 | <b>14.4</b>                 | <b>CMR Imaging Techniques</b> . . . . .                                            | 238 |
| <b>References</b> . . . . . | 212                                                                             |     | 14.4.1                      | General Aspects . . . . .                                                          | 238 |
| <b>13</b>                   | <b>Adult Valvular Disease</b> . . . . .                                         | 216 | 14.4.2                      | Performing CMR in Newborns and Children . . . . .                                  | 239 |
|                             | Bernhard L. Gerber and Jochen Spiess                                            |     | 14.4.3                      | CMR Protocols . . . . .                                                            | 239 |
| <b>13.1</b>                 | <b>Introduction</b> . . . . .                                                   | 216 | 14.4.4                      | Quantitative Analysis of Morphology and Function . . . . .                         | 240 |
| <b>13.2</b>                 | <b>General Principles of Evaluation of Valve Disease by CMR</b> . . . . .       | 216 | 14.4.5                      | Normal Values of Cardiac Volumes/Function . . . . .                                | 240 |



|              |                                                                                                                   |     |                         |                                                                                 |     |
|--------------|-------------------------------------------------------------------------------------------------------------------|-----|-------------------------|---------------------------------------------------------------------------------|-----|
| <b>14.5</b>  | <b>Anomalies of the Atrial and Visceral Situs</b> .....                                                           | 241 | <b>14.11</b>            | <b>Anomalies of the Aorta</b> .....                                             | 267 |
| <b>14.6</b>  | <b>Anomalies of the Atria, Systemic and Pulmonary Veins</b> .....                                                 | 242 | 14.11.1                 | Coarctation of the Aorta (CoA) .....                                            | 267 |
| 14.6.1       | Atrial Septal Defect (ASD) .....                                                                                  | 242 | 14.11.2                 | Supravalvular Aortic Stenosis .....                                             | 269 |
| 14.6.2       | Pulmonary Vein Anomalies .....                                                                                    | 243 | <b>14.12</b>            | <b>Congenital Valvular Disease</b> .....                                        | 269 |
| 14.6.3       | Anomalies of the Systemic Veins .....                                                                             | 246 | <b>14.13</b>            | <b>MR Imaging after Surgical Palliation</b> ...                                 | 270 |
| <b>14.7</b>  | <b>Ventricular Malformations and Ventricular Septal Defects</b> .....                                             | 246 | 14.13.1                 | Separation of Circulation at the Atrial Level (Fontan Procedure) .....          | 270 |
| 14.7.1       | Ventricular Septal Defects (VSD) and Atrioventricular Septal Defects (AVSD) ..                                    | 246 | 14.13.2                 | Surgical Palliation Prior to Correction or Fontan Procedure .....               | 270 |
| 14.7.2       | Intracavitary Right Ventricular Stenosis .....                                                                    | 248 | <b>14.14</b>            | <b>Conclusions and Future Perspectives</b> ...                                  | 271 |
| 14.7.3       | Pulmonary Atresia (PAA) with Intact Interventricular Septum .....                                                 | 248 | <b>References</b> ..... |                                                                                 | 271 |
| 14.7.4       | Ebstein's Anomaly .....                                                                                           | 249 | <b>15</b>               | <b>Pericardial Diseases</b> .....                                               | 273 |
| 14.7.5       | Tricuspid Atresia (TA) .....                                                                                      | 250 |                         | Vinzenz Hombach                                                                 |     |
| 14.7.6       | Subvalvular Aortic Stenosis .....                                                                                 | 252 | <b>15.1</b>             | <b>Anatomy and Function of the Pericardium</b> .....                            | 273 |
| 14.7.7       | Hypoplastic Left Heart Syndrome (HLHS) ..                                                                         | 252 | <b>15.2</b>             | <b>CMR Protocols</b> .....                                                      | 273 |
| 14.7.8       | Univentricular Atrioventricular Connections .....                                                                 | 254 | <b>15.3</b>             | <b>Pericarditis and Pericardial Effusion</b> ....                               | 274 |
| <b>14.8</b>  | <b>Conotruncal Defects</b> .....                                                                                  | 256 | <b>15.4</b>             | <b>Constrictive Pericarditis</b> .....                                          | 277 |
| 14.8.1       | Tetralogy of Fallot (TOF) and Pulmonary Atresia with Ventricular Septal Defect and Pulmonary Valve Agenesis ..... | 256 | <b>15.5</b>             | <b>Pericardial Cysts, Defects and Diverticula</b> .....                         | 279 |
| 14.8.2       | Truncus Arteriosus Communis (TAC) .....                                                                           | 258 | <b>15.6</b>             | <b>Tumors of the Pericardium</b> .....                                          | 280 |
| 14.8.3       | Double Outlet Right Ventricle (DORV) .....                                                                        | 259 | 15.6.1                  | Mesothelioma .....                                                              | 280 |
| 14.8.4       | D-Transposition of the Great Arteries (TGA) .....                                                                 | 261 | 15.6.2                  | Extracardiac (Secondary) Tumors .....                                           | 281 |
| 14.8.5       | Congenitally Corrected Transposition of the Great Arteries (ccTGA) .....                                          | 262 | <b>15.7</b>             | <b>Summary and Conclusions</b> .....                                            | 281 |
| <b>14.9</b>  | <b>Aortic Arch Anomalies (including Ring Formation)</b> .....                                                     | 263 | <b>References</b> ..... |                                                                                 | 282 |
| 14.9.1       | Anomalies with Left Aortic Arch .....                                                                             | 263 | <b>16</b>               | <b>Cardiac Magnetic Resonance Control of Cardiovascular Interventions</b> ..... | 283 |
| 14.9.2       | Anomalies with Right Aortic Arch .....                                                                            | 264 |                         | Vinzenz Hombach                                                                 |     |
| 14.9.3       | Double Aortic Arch .....                                                                                          | 265 | <b>16.1</b>             | <b>Introduction</b> .....                                                       | 283 |
| 14.9.4       | Persistent Fifth Aortic Arch .....                                                                                | 265 | <b>16.2</b>             | <b>Medical Treatments</b> .....                                                 | 284 |
| 14.9.5       | Interrupted Aortic Arch .....                                                                                     | 265 | 16.2.1                  | Heart Failure (HF) .....                                                        | 284 |
| 14.9.6       | Aortopulmonary Window .....                                                                                       | 266 | 16.2.2                  | Chelation Therapy in Thalassemia Major ...                                      | 284 |
| 14.9.7       | Patent Ductus Arteriosus (PDA) Botalli .....                                                                      | 266 | <b>16.3</b>             | <b>Catheter Ablation of Cardiac Arrhythmias</b> .....                           | 284 |
| 14.9.8       | "Aberrant" Truncus Brachiocephalicus .....                                                                        | 266 | 16.3.1                  | Electro-Anatomic Mapping .....                                                  | 284 |
| 14.9.9       | Cervical Aortic Arch .....                                                                                        | 266 | 16.3.2                  | Assessment and Implications of Radiofrequency-Induced Scars .....               | 285 |
| <b>14.10</b> | <b>Anomalies of the Pulmonary Artery</b> ....                                                                     | 267 |                         |                                                                                 |     |
| 14.10.1      | Origin of one Pulmonary Artery from the Ascending Aorta .....                                                     | 267 |                         |                                                                                 |     |
| 14.10.2      | Origin of Left Pulmonary Artery from the Right Pulmonary Artery ("Pulmonary Sling") .....                         | 267 |                         |                                                                                 |     |

|                         |                                                                                                    |            |                         |                                                                                                                  |            |
|-------------------------|----------------------------------------------------------------------------------------------------|------------|-------------------------|------------------------------------------------------------------------------------------------------------------|------------|
| 16.3.3                  | Future Role of CMR Imaging<br>in Radiofrequency Ablation .....                                     | 286        | 17.6.3                  | Papillary Fibroelastoma .....                                                                                    | 307        |
| <b>16.4</b>             | <b>Myocardial Revascularisation .....</b>                                                          | <b>286</b> | 17.6.4                  | Fibroma .....                                                                                                    | 308        |
| 16.4.1                  | Percutaneous Coronary Interventions (PCI) ..                                                       | 286        | 17.6.5                  | Rhabdomyoma .....                                                                                                | 309        |
| 16.4.2                  | Functional Outcome after Revascularization ..                                                      | 286        | 17.6.6                  | Pheochromocytoma (Paraganglioma) .....                                                                           | 309        |
| <b>16.5</b>             | <b>Catheter-Based Closure of Atrial Septal<br/>Defects and of Patent Foramen Ovale ..</b>          | <b>287</b> | 17.6.7                  | Hemangioma .....                                                                                                 | 310        |
| <b>16.6</b>             | <b>Interventional and<br/>Surgical Septal Ablation in HOCM .....</b>                               | <b>288</b> | 17.6.8                  | Teratoma .....                                                                                                   | 311        |
| <b>16.7</b>             | <b>Transcatheter Aortic Valve<br/>Implantation (TAVI) .....</b>                                    | <b>289</b> | <b>17.7</b>             | <b>Malignant Cardiac Tumors .....</b>                                                                            | <b>311</b> |
| <b>16.8</b>             | <b>Interventional Treatment<br/>or Operative Repair of Aortic Dissection<br/>or Aneurysm .....</b> | <b>290</b> | 17.7.1                  | Angiosarcoma .....                                                                                               | 312        |
| 16.8.1                  | Stenting .....                                                                                     | 290        | 17.7.2                  | Rhabdomyosarcoma .....                                                                                           | 313        |
| 16.8.2                  | Operative Repair .....                                                                             | 292        | 17.7.3                  | Leiomyosarcoma .....                                                                                             | 313        |
| <b>16.9</b>             | <b>Myocardial Stem Cell Therapy .....</b>                                                          | <b>293</b> | 17.7.4                  | Fibrosarcoma, Liposarcoma<br>and Osteosarcoma .....                                                              | 314        |
| 16.9.1                  | Animal Studies .....                                                                               | 293        | 17.7.5                  | Malignant Fibrous Histiocytoma .....                                                                             | 315        |
| 16.9.2                  | Human Studies .....                                                                                | 293        | 17.7.6                  | Malignant Lymphoma .....                                                                                         | 316        |
| <b>16.10</b>            | <b>Interventional and Surgical Treatment<br/>for Congenital Heart Disease .....</b>                | <b>294</b> | <b>17.8</b>             | <b>Secondary Cardiac Tumors<br/>(Cardiac Metastasis) .....</b>                                                   | <b>317</b> |
| 16.10.1                 | Tetralogy of Fallot (TOF) .....                                                                    | 294        | <b>17.9</b>             | <b>Non-Neoplastic Cardiac Masses .....</b>                                                                       | <b>318</b> |
| 16.10.2                 | Pulmonary Homograft Failure .....                                                                  | 294        | 17.9.1                  | Intracardiac Thrombi .....                                                                                       | 318        |
| 16.10.3                 | Coarctation of the Aorta (CoA) .....                                                               | 294        | 17.9.2                  | Cardiac Echinococcus Cysts .....                                                                                 | 319        |
| 16.10.4                 | Summary and Conclusions .....                                                                      | 296        | <b>17.10</b>            | <b>Normal Variants of the Heart .....</b>                                                                        | <b>320</b> |
| <b>16.11</b>            | <b>Surgery for Adult Cardiovascular<br/>Disease .....</b>                                          | <b>296</b> | 17.10.1                 | Lipomatous Hypertrophy<br>of the Interatrial Septum (LHAS) .....                                                 | 320        |
| <b>16.12</b>            | <b>Conclusions and Future Perspectives ...</b>                                                     | <b>299</b> | 17.10.2                 | Atrial Septal Aneurysm .....                                                                                     | 320        |
| <b>References .....</b> | <b>299</b>                                                                                         |            | 17.10.3                 | Prominent Crista Terminalis .....                                                                                | 321        |
|                         |                                                                                                    |            | 17.10.4                 | Chiari Network .....                                                                                             | 321        |
|                         |                                                                                                    |            | <b>17.11</b>            | <b>Summary and Conclusions .....</b>                                                                             | <b>321</b> |
|                         |                                                                                                    |            | <b>References .....</b> | <b>321</b>                                                                                                       |            |
| <b>17</b>               | <b>Cardiac Tumors and Masses .....</b>                                                             | <b>302</b> | <b>18</b>               | <b>Pulmonary Circulation .....</b>                                                                               | <b>323</b> |
|                         | Johannes Schwab and Vinzenz Hombach                                                                |            |                         | Vinzenz Hombach                                                                                                  |            |
| <b>17.1</b>             | <b>Definition .....</b>                                                                            | <b>302</b> | <b>18.1</b>             | <b>Physiology of Pulmonary Circulation ...</b>                                                                   | <b>323</b> |
| <b>17.2</b>             | <b>Spectrum of Tumors .....</b>                                                                    | <b>302</b> | <b>18.2</b>             | <b>CMR Protocols .....</b>                                                                                       | <b>324</b> |
| <b>17.3</b>             | <b>Clinical Presentation .....</b>                                                                 | <b>303</b> | 18.2.1                  | Right and Left Ventricular Volumes<br>and Function .....                                                         | 324        |
| <b>17.4</b>             | <b>CMR Protocols .....</b>                                                                         | <b>303</b> | 18.2.2                  | Velocity-Encoded Flow Mapping .....                                                                              | 324        |
| <b>17.5</b>             | <b>Differentiating Features .....</b>                                                              | <b>304</b> | 18.2.3                  | Magnetic Resonance Angiography (MRA) ...                                                                         | 324        |
| <b>17.6</b>             | <b>Benign Cardiac Tumors .....</b>                                                                 | <b>304</b> | 18.2.4                  | Technical Aspects .....                                                                                          | 325        |
| 17.6.1                  | Myxoma .....                                                                                       | 304        | <b>18.3</b>             | <b>Pulmonary Arterial Hypertension (PAH) ..</b>                                                                  | <b>325</b> |
| 17.6.2                  | Lipoma .....                                                                                       | 306        | <b>18.4</b>             | <b>Pulmonary Arterial Hypertension<br/>Associated with Significant Venous<br/>or Capillary Involvement .....</b> | <b>330</b> |



|                                                       |                                                                                                  |     |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------|-----|
| <b>18.5</b>                                           | <b>Pulmonary Hypertension with Left Heart Disease</b>                                            | 330 |
| <b>18.6</b>                                           | <b>Pulmonary Arterial Hypertension Associated with Lung Disease and/or Hypoxemia</b>             | 331 |
| <b>18.7</b>                                           | <b>Pulmonary Arterial Hypertension due to Acute or Chronic Thrombotic and/or Embolic Disease</b> | 331 |
| 18.7.1                                                | Acute Pulmonary Embolism (PE)                                                                    | 331 |
| 18.7.2                                                | Chronic Thromboembolic Pulmonary Hypertension (CTEPH)                                            | 333 |
| <b>18.8</b>                                           | <b>Diseases of the Pulmonary Vessels</b>                                                         | 333 |
| 18.8.1                                                | Pulmonary Arterial Diseases                                                                      | 333 |
| 18.8.2                                                | Pulmonary Venous Diseases                                                                        | 334 |
| <b>18.9</b>                                           | <b>Malformations of the Lung Parenchyma</b>                                                      | 335 |
| 18.9.1                                                | Bronchopulmonary Sequestration                                                                   | 335 |
| 18.9.2                                                | Agnesia, Aplasia and Hypoplasia of Lung Parenchyma                                               | 337 |
| <b>References</b>                                     |                                                                                                  | 337 |
| <b>19</b>                                             | <b>Diseases of the Thoracic and Abdominal Aorta</b>                                              | 340 |
| Christina Heilmaier, Florian Vogt and Jörg Barkhausen |                                                                                                  |     |
| <b>19.1</b>                                           | <b>Introduction</b>                                                                              | 340 |
| <b>19.2</b>                                           | <b>MRI Techniques</b>                                                                            | 340 |
| 19.2.1                                                | MR Angiography (MRA)                                                                             | 340 |
| 19.2.2                                                | Time-Resolved MRA                                                                                | 341 |
| 19.2.3                                                | Whole-Body MRA                                                                                   | 342 |
| <b>19.3</b>                                           | <b>Diseases of the Thoracic Aorta</b>                                                            | 343 |
| 19.3.1                                                | Aortic Aneurysm (Aneurysma Verum)                                                                | 343 |
| 19.3.2                                                | Dissecting Aneurysm                                                                              | 345 |
| 19.3.3                                                | Intramural Hematoma and Penetrating Ulcer                                                        | 348 |
| <b>19.4</b>                                           | <b>Aortitis</b>                                                                                  | 350 |
| <b>19.5</b>                                           | <b>Diseases of the Abdominal Aorta</b>                                                           | 351 |
| 19.5.1                                                | Aneurysm                                                                                         | 351 |
| 19.5.2                                                | Inflammatory Aneurysm                                                                            | 352 |
| 19.5.3                                                | Leriche Syndrome                                                                                 | 352 |
| <b>19.6</b>                                           | <b>Conclusions and Future Perspectives</b>                                                       | 353 |

|                                        |                                                                  |     |
|----------------------------------------|------------------------------------------------------------------|-----|
| <b>20</b>                              | <b>Diseases of the Cerebral and Peripheral Arteries</b>          | 355 |
| Mathias Goyen and Christoph U. Herborn |                                                                  |     |
| <b>20.1</b>                            | <b>Cerebral Arteries</b>                                         | 355 |
| 20.1.1                                 | Extracranial MRA                                                 | 355 |
| 20.1.2                                 | Intracranial MRA                                                 | 357 |
| 20.1.3                                 | Perfusion                                                        | 360 |
| <b>20.2</b>                            | <b>Peripheral Arteries</b>                                       | 361 |
| 20.2.1                                 | General Aspects                                                  | 361 |
| 20.2.2                                 | Contrast-Enhanced MRA                                            | 361 |
| 20.2.3                                 | Whole-Body 3D Contrast-Enhanced MRA                              | 362 |
| 20.2.4                                 | Indications for CE-MRA in Peripheral Arterial Diseases           | 362 |
| <b>References</b>                      |                                                                  | 363 |
| <b>21</b>                              | <b>Incidental Findings at Cardiac Magnetic Resonance Imaging</b> | 366 |
| Sandra Pauls and Christian Schumann    |                                                                  |     |
| <b>21.1</b>                            | <b>Prevalence</b>                                                | 366 |
| <b>21.2</b>                            | <b>Significance of CMR versus Multi-Detector CT Imaging</b>      | 367 |
| <b>21.3</b>                            | <b>Topographic Distribution</b>                                  | 367 |
| <b>21.4</b>                            | <b>Anterior Mediastinal Masses</b>                               | 367 |
| <b>21.5</b>                            | <b>Middle Mediastinal Masses</b>                                 | 368 |
| <b>21.6</b>                            | <b>Posterior Mediastinal Masses</b>                              | 369 |
| <b>21.7</b>                            | <b>Diffuse Mediastinal Diseases</b>                              | 369 |
| <b>21.8</b>                            | <b>Diseases of the Lung Parenchyma</b>                           | 370 |
| <b>21.9</b>                            | <b>Tracheobronchial Diseases</b>                                 | 372 |
| <b>21.10</b>                           | <b>Diseases of the Pleura</b>                                    | 373 |
| <b>21.11</b>                           | <b>Diseases of the Thoracic Wall</b>                             | 375 |
| <b>21.12</b>                           | <b>Diseases of the Upper Abdomen</b>                             | 375 |
| <b>21.13</b>                           | <b>Summary and Conclusions</b>                                   | 375 |
| <b>References</b>                      |                                                                  | 376 |

## Part III

### Innovative and Experimental Imaging Techniques

#### 22 High-Field Cardiac Magnetic Resonance ..... 379

Matthias Stuber and Peter R. Luijten

##### 22.1 Basic Principles – Why Higher Fields? .. 379

##### 22.2 Challenges for Imaging at High Fields .. 379

###### 22.2.1 Specific Absorption Rate (SAR) ..... 379

###### 22.2.2 $B_1$ Inhomogeneities ..... 380

###### 22.2.3 Magnetohydrodynamic Effect ..... 380

##### 22.3 Dedicated Developments ..... 381

###### 22.3.1 Multi-Transmit Options and $B_1$ Shimming .. 381

##### 22.4 Clinical Benefit ..... 381

###### 22.4.1 Global Function ..... 381

###### 22.4.2 Regional Function ..... 384

###### 22.4.3 Coronary Angiography ..... 385

###### 22.4.4 Coronary Vessel Wall Imaging and Plaque Visualization ..... 387

###### 22.4.5 Perfusion and Late Enhancement ..... 387

###### 22.4.6 Spectroscopy ..... 389

##### 22.5 Conclusions and Future Perspectives ... 390

##### References ..... 390

#### 23 Cardiac Magnetic Resonance Imaging in Small Animal Models .... 393

Volker Herold, Karl-Heinz Hiller  
and Peter M. Jakob

##### 23.1 Introduction ..... 393

##### 23.2 MR-Hardware and Animal Preparation for CMRI in Small Animals ..... 394

##### 23.3 Structural and Functional Analysis in Small Animals ..... 395

###### 23.3.1 Cine-CMR – Myocardial Volumes, Function and Mass .... 395

###### 23.3.2 Regional Wall Motion Analysis ..... 396

###### 23.3.3 Myocardial Perfusion and Blood Volume .... 397

###### 23.3.4 Measurement of Blood Flow in Aorta and Coronary Arteries ..... 399

###### 23.3.5 Vessel Wall and Atherosclerosis Imaging .... 400

##### 23.4 Contrast-Enhanced and Molecular MRI ..... 402

###### 23.4.1 Late Enhancement ..... 402

###### 23.4.2 Molecular MRI ..... 403

##### 23.5 Conclusions and Future Perspectives ... 404

##### References ..... 404

#### 24 Cardiac Magnetic Resonance Spectroscopy ..... 407

Cameron Holloway, Kieran Clarke  
and Stefan Neubauer

##### 24.1 Introduction ..... 407

##### 24.2 Physics of MR Spectroscopy ..... 408

##### 24.3 Experimental Studies ..... 409

###### 24.3.1 $^{31}\text{P}$ -MRS Studies ..... 409

###### 24.3.2 Other MRS-Detectable Nuclei ( $^1\text{H}$ , $^{13}\text{C}$ , $^{23}\text{Na}$ ) ..... 412

###### 24.3.3 Hyperpolarised $^{13}\text{C}$ -Studies ..... 413

###### 24.3.4 Experimental Studies in Genetically Altered Mice ..... 414

##### 24.4 Clinical Studies ..... 414

###### 24.4.1 Methods for Clinical Cardiac Spectroscopy .. 414

###### 24.4.2 Normal Values for $^{31}\text{P}$ -Spectroscopy ..... 416

###### 24.4.3 Coronary Heart Disease ..... 417

###### 24.4.4 Valvular Heart Disease ..... 419

###### 24.4.5 Hypertension and Athletes ..... 419

###### 24.4.6 Diabetes, Obesity and Diets ..... 420

###### 24.4.7 Heart Failure ..... 420

###### 24.4.8 Heart Transplantation ..... 422

###### 24.4.9 Genetic Heart Muscle Disease ..... 422

##### 24.5 Conclusions and Future Perspectives ... 423

##### References ..... 424

#### 25 Interventional Cardiovascular Magnetic Resonance Imaging ..... 426

Maythem Saeed and Mark W. Wilson

##### 25.1 Introduction ..... 426

##### 25.2 Basic Principles ..... 426

##### 25.3 Hardware and Software ..... 427

|                         |                                                                                       |     |                         |                                                                            |     |
|-------------------------|---------------------------------------------------------------------------------------|-----|-------------------------|----------------------------------------------------------------------------|-----|
| <b>25.4</b>             | <b>Catheter Tracking and Interventional Devices</b> .....                             | 428 | <b>26.4</b>             | <b>CT Coronary Angiography</b> .....                                       | 444 |
| 25.4.1                  | Passive Catheter Tracking .....                                                       | 428 | 26.4.1                  | Coronary Anatomy .....                                                     | 444 |
| 25.4.2                  | Active Catheter Tracking .....                                                        | 428 | 26.4.2                  | Clinical Role of CT Coronary Angiography ..                                | 444 |
| 25.4.3                  | Magnetic Catheter Steering .....                                                      | 429 | <b>26.5</b>             | <b>CT of Cardiac Structure and Function</b> ...                            | 449 |
| <b>25.5</b>             | <b>Endovascular Interventions</b> .....                                               | 429 | <b>26.6</b>             | <b>Myocardial Perfusion and Viability</b> .....                            | 450 |
| <b>25.6</b>             | <b>CMR-Guided Catheterization and Interventions in Congenital Heart Disease</b> ..... | 430 | <b>26.7</b>             | <b>Pericardial Disease</b> .....                                           | 451 |
| <b>25.7</b>             | <b>ICMR-Guided Gene and Stem Cell Delivery</b> .....                                  | 432 | <b>26.8</b>             | <b>Diagnosis of Cardiac Masses</b> .....                                   | 451 |
| <b>25.8</b>             | <b>Summary</b> .....                                                                  | 434 | <b>26.9</b>             | <b>CT Imaging for Left Atrial Electrophysiology Applications</b> .....     | 451 |
| <b>References</b> ..... | 434                                                                                   |     | <b>26.10</b>            | <b>Angiography of the Thoracic and Abdominal Aorta</b> .....               | 453 |
| <b>26</b>               | <b>Cardiovascular Computed Tomography</b> .....                                       | 438 | <b>26.11</b>            | <b>Role of CT for Transcatheter Aortic Valve Implantation (TAVI)</b> ..... | 454 |
|                         | Martin Hoffmann, Sabine Wuchenauer, Horst Brunner and Oliver Klass                    |     | <b>26.12</b>            | <b>Detection of Pulmonary Embolism</b> .....                               | 457 |
| <b>26.1</b>             | <b>Introduction</b> .....                                                             | 438 | <b>26.13</b>            | <b>Conclusions and Future Perspectives</b> ...                             | 458 |
| <b>26.2</b>             | <b>Basic Principles and Technology</b> .....                                          | 438 | 26.13.1                 | Basic Principle of Spectral CT .....                                       | 458 |
| 26.2.1                  | Heart Rate Reduction and Vasodilatation ...                                           | 440 | 26.13.2                 | The Unobscured 3D Luminogram .....                                         | 458 |
| 26.2.2                  | Breath Holding and Positioning .....                                                  | 440 | 26.13.3                 | Potential for Plaque Imaging .....                                         | 459 |
| 26.2.3                  | Contrast Injection .....                                                              | 440 | <b>References</b> ..... | 460                                                                        |     |
| 26.2.4                  | Best Phase Selection .....                                                            | 441 |                         |                                                                            |     |
| <b>26.3</b>             | <b>Coronary Artery Calcifications and Plaque Imaging</b> .....                        | 441 | <b>Index</b> .....      | 462                                                                        |     |
| 26.3.1                  | Calcium Scoring .....                                                                 | 441 |                         |                                                                            |     |
| 26.3.2                  | Non-Calcified Plaque Imaging .....                                                    | 442 |                         |                                                                            |     |